𝔖 Bobbio Scriptorium
✦   LIBER   ✦

150 Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer

✍ Scribed by H. Koeppen; W. Ince; E. Holmgren; M. Zhang; P. Tobin; R. Zhang; W. Novotny; K. Hillan

Book ID
118621333
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
134 KB
Volume
2
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Bevacizumab in combination with irinotec
Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer: Abstracted from: Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42
✍ Michael A. Choti πŸ“‚ Article πŸ“… 2004 πŸ› Elsevier Science 🌐 English βš– 246 KB
Efficacy and safety of bevacizumab-based
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)
✍ Ducreux, M.; Adenis, A.; Pignon, J.-P.; FranΓ§ois, E.; Chauffert, B.; IchantΓ©, J. πŸ“‚ Article πŸ“… 2013 πŸ› Elsevier Science 🌐 English βš– 602 KB